Moderna Inc. is suing a Burlington construction firm that worked on its Marlborough manufacturing facility for “defective ...

The most recent trading session ended with Moderna (MRNA) standing at $24.73, reflecting a -1.85% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily ...

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

Shares of Moderna ( MRNA 6.82%) are falling on Monday. The company's stock lost 7.9% as of 1:30 p.m. ET and was down as much as 13.9% earlier in the day. The steep decline comes as the S&P 500 and ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and Drug Administration’s top vaccine official has resigned. Watch these key ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

In a report released today, Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...